TY - JOUR
T1 - Cortical control of VTA function and influence on nicotine reward
AU - Wu, Jie
AU - Gao, Ming
AU - Shen, Jian Xin
AU - Shi, Wei Xing
AU - Oster, Andrew M.
AU - Gutkin, Boris S.
N1 - Funding Information:
Work toward this project was supported by the Barrow Neurological Foundation and by grants from the Arizona Biomedical Research Commission ( 0028 and 0057 ), the Institute for Mental Health Research, Philip Morris International through their External Research Program, and the National Institutes of Health ( R01 NS040417 and R01 DA015389 ). BSG and AMO were supported in part by the ANR “Dopanic” grant, and AMO was supported in part by a NERF grant.
PY - 2013
Y1 - 2013
N2 - Tobacco use is a major public health problem. Nicotine acts on widely distributed nicotinic acetylcholine receptors (nAChRs) in the brain and excites dopamine (DA) neurons in the ventral tegmental area (VTA). The elicited increase of DA neuronal activity is thought to be an important mechanism for nicotine reward and subsequently the transition to addiction. However, the current understanding of nicotine reward is based predominantly on the data accumulated from in vitro studies, often from VTA slices. Isolated VTA slices artificially terminate communications between neurons in the VTA and other brain regions that may significantly alter nicotinic effects. Consequently, the mechanisms of nicotinic excitation of VTA DA neurons under in vivo conditions have received only limited attention. Building upon the existing knowledge acquired in vitro, it is now time to elucidate the integrated mechanisms of nicotinic reward on intact systems that are more relevant to understanding the action of nicotine or other addictive drugs. In this review, we summarize recent studies that demonstrate the impact of prefrontal cortex (PFC) on the modulation of VTA DA neuronal function and nicotine reward. Based on existing evidence, we propose a new hypothesis that PFC-VTA functional coupling serves as an integration mechanism for nicotine reward. Moreover, addiction may develop due to nicotine perturbing the PFC-VTA coupling and thereby eliminating the PFC-dependent cognitive control over behavior.
AB - Tobacco use is a major public health problem. Nicotine acts on widely distributed nicotinic acetylcholine receptors (nAChRs) in the brain and excites dopamine (DA) neurons in the ventral tegmental area (VTA). The elicited increase of DA neuronal activity is thought to be an important mechanism for nicotine reward and subsequently the transition to addiction. However, the current understanding of nicotine reward is based predominantly on the data accumulated from in vitro studies, often from VTA slices. Isolated VTA slices artificially terminate communications between neurons in the VTA and other brain regions that may significantly alter nicotinic effects. Consequently, the mechanisms of nicotinic excitation of VTA DA neurons under in vivo conditions have received only limited attention. Building upon the existing knowledge acquired in vitro, it is now time to elucidate the integrated mechanisms of nicotinic reward on intact systems that are more relevant to understanding the action of nicotine or other addictive drugs. In this review, we summarize recent studies that demonstrate the impact of prefrontal cortex (PFC) on the modulation of VTA DA neuronal function and nicotine reward. Based on existing evidence, we propose a new hypothesis that PFC-VTA functional coupling serves as an integration mechanism for nicotine reward. Moreover, addiction may develop due to nicotine perturbing the PFC-VTA coupling and thereby eliminating the PFC-dependent cognitive control over behavior.
KW - Dopamine neurons
KW - Nicotine reward
KW - Nicotinic acetylcholine receptor
KW - Prefrontal cortex
KW - Ventral tegmental area
UR - http://www.scopus.com/inward/record.url?scp=84885609305&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885609305&partnerID=8YFLogxK
U2 - 10.1016/j.bcp.2013.07.013
DO - 10.1016/j.bcp.2013.07.013
M3 - Review article
SN - 0006-2952
VL - 86
SP - 1173
EP - 1180
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 8
ER -